The citrate-free high-concentration formulation injection has been approved to treat a myriad of arthritis conditions as well as ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
“The FDA approval of Hyrimoz HCF builds on the already approved and well-established Sandoz global biosimilar portfolio in immunology,” the news release states. “When it launches, Hyrimoz HCF will represent the first launch of a Sandoz biosimilar in the U.S. market in this specific disease space.”
Hyrimoz HCF met all objectives and showed similar safety levels, pharmacokinetics and immunogenicity as the already FDA-approved adalimumab 50 mg/mL to which it was compared.
As a result of the FDA’s approval, Sandoz plans to launch Hyrimoz for availability in the U.S. beginning July 1.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.